Shruti Agrawal

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Matthew D. Hellmann, Naiyer A. Rizvi, Jonathan W. Goldman et al. · The Lancet Oncology · 2016 · 961 citations · Full text

Pharmacy, Oncology, Pharmacology +13

Whole-genome sequencing reveals host factors underlying critical COVID-19

Athanasios Kousathanas, Erola Pairo‐Castineira, Konrad Rawlik et al. · Nature · 2022 · 347 citations · Full text

Life Sciences, Infectious Diseases, Molecular Genetics +17

Dasatinib combined with docetaxel for castration‐resistant prostate cancer

John C. Araujo, Paul Mathew, Andrew J. Armstrong et al. · Cancer · 2011 · 149 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Phase 1 pharmacokinetic and drug‐interaction study of dasatinib in patients with advanced solid tumors

Faye M. Johnson, Shruti Agrawal, Howard A. Burris et al. · Cancer · 2010 · 124 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +11

Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects

Timothy Eley, Feng Luo, Shruti Agrawal et al. · The Journal of Clinical Pharmacology · 2009 · 104 citations

Pharmacy, Pharmacokinetics, Pharmacology +13